{
    "hands_on_practices": [
        {
            "introduction": "The clinical manifestation of Scleroderma Renal Crisis (SRC) is centered on the rapid deterioration of kidney function. Therefore, the first step in the diagnostic process is to formally identify and quantify the presence of Acute Kidney Injury (AKI). This practice provides a foundational exercise in applying the internationally recognized Kidney Disease: Improving Global Outcomes (KDIGO) criteria, which involves calculating the change in serum creatinine from a recent baseline. Mastering this initial step is critical, as it is the trigger for considering SRC and initiating an urgent and specific diagnostic workup .",
            "id": "4895563",
            "problem": "A 46-year-old patient with diffuse cutaneous systemic sclerosis presents with new-onset severe hypertension and headache. Over the prior month, the patient’s outpatient serum creatinine was stable at a baseline of $1.2\\ \\mathrm{mg/dL}$. On admission for suspected scleroderma renal crisis, the serum creatinine measured $1.8\\ \\mathrm{mg/dL}$ after $24$ hours. Using only fundamental definitions, first compute the fractional (unitless) increase in serum creatinine from baseline to the current value, expressed as a decimal fraction without a percent sign. Round your final numerical result to three significant figures. Then, using the consensus definitions from Kidney Disease: Improving Global Outcomes (KDIGO) for Acute Kidney Injury (AKI), reason qualitatively (no additional numerical output required) about how this magnitude and time course of change would be interpreted within AKI staging in the context of scleroderma renal crisis. Report only the computed decimal fraction as your final answer.",
            "solution": "The problem is deemed valid as it is scientifically grounded, well-posed, objective, and contains sufficient information for a unique solution. It presents a clinically realistic scenario requiring the application of a fundamental mathematical definition and subsequent interpretation using established medical guidelines.\n\nThe initial step is to compute the fractional increase in serum creatinine. Let $C_{base}$ be the baseline serum creatinine and $C_{adm}$ be the serum creatinine on admission. The problem provides the following values:\n$$ C_{base} = 1.2\\ \\mathrm{mg/dL} $$\n$$ C_{adm} = 1.8\\ \\mathrm{mg/dL} $$\n\nThe absolute increase in serum creatinine, denoted as $\\Delta C$, is the difference between the admission value and the baseline value:\n$$ \\Delta C = C_{adm} - C_{base} = 1.8\\ \\mathrm{mg/dL} - 1.2\\ \\mathrm{mg/dL} = 0.6\\ \\mathrm{mg/dL} $$\n\nThe fractional increase, which we will denote by $f_{\\text{inc}}$, is defined as the ratio of the absolute increase to the original baseline value. This provides a unitless measure of the relative change.\n$$ f_{\\text{inc}} = \\frac{\\Delta C}{C_{base}} = \\frac{C_{adm} - C_{base}}{C_{base}} $$\n\nSubstituting the given numerical values into this expression yields:\n$$ f_{\\text{inc}} = \\frac{1.8 - 1.2}{1.2} = \\frac{0.6}{1.2} $$\n\nPerforming the division gives the exact decimal value:\n$$ f_{\\text{inc}} = 0.5 $$\n\nThe problem requires the result to be rounded to three significant figures. To express $0.5$ with three significant figures, we append trailing zeros.\n$$ f_{\\text{inc}} \\approx 0.500 $$\n\nThe second part of the task requires a qualitative reasoning based on the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for Acute Kidney Injury (AKI). The KDIGO guidelines define and stage AKI based on changes in serum creatinine or urine output. Focusing on the serum creatinine criteria, AKI is defined as an increase in serum creatinine ($\\text{SCr}$) by $\\geq 0.3\\ \\mathrm{mg/dL}$ within $48$ hours, or an increase to $\\geq 1.5$ times baseline which is known or presumed to have occurred within the prior $7$ days.\n\nIn this case, the patient's serum creatinine increased by $\\Delta C = 0.6\\ \\mathrm{mg/dL}$ over a period of $24$ hours. This absolute increase is greater than the threshold of $0.3\\ \\mathrm{mg/dL}$ within $48$ hours, thus satisfying the definition of AKI.\n\nTo stage the AKI, we evaluate the magnitude of the increase relative to baseline. The ratio of the admission creatinine to the baseline creatinine is:\n$$ \\frac{C_{adm}}{C_{base}} = \\frac{1.8\\ \\mathrm{mg/dL}}{1.2\\ \\mathrm{mg/dL}} = 1.5 $$\nAccording to the KDIGO staging criteria:\n- **Stage 1**: Increase in $\\text{SCr}$ to $1.5-1.9$ times baseline.\n- **Stage 2**: Increase in $\\text{SCr}$ to $2.0-2.9$ times baseline.\n- **Stage 3**: Increase in $\\text{SCr}$ to $\\geq 3.0$ times baseline, or increase in $\\text{SCr}$ to $\\geq 4.0\\ \\mathrm{mg/dL}$, or initiation of renal replacement therapy.\n\nThe patient's creatinine level has risen to exactly $1.5$ times the baseline value. This meets the minimum threshold for Stage $1$ AKI. Therefore, based on the provided data, the patient's condition would be classified as Stage $1$ Acute Kidney Injury. This formal staging is critical in the context of scleroderma renal crisis, as it quantifies the severity of the acute kidney insult and helps guide the urgency and intensity of treatment, which typically involves aggressive blood pressure control with angiotensin-converting enzyme (ACE) inhibitors.\n\nThe final answer required is only the numerical value of the fractional increase.",
            "answer": "$$\\boxed{0.500}$$"
        },
        {
            "introduction": "While classic SRC presents with malignant hypertension, a significant subset of patients develop \"normotensive\" SRC, creating a difficult diagnostic challenge where the condition can mimic more common causes of AKI, such as prerenal azotemia. This problem requires you to analyze a complex set of laboratory data to distinguish between these two entities. The key learning objective is to understand that while renal perfusion indices like the fractional excretion of sodium ($FENa$) can be misleadingly similar in both conditions, the presence of thrombotic microangiopathy—evidenced by schistocytes, thrombocytopenia, and hemolysis—is the specific hallmark that unmasks SRC .",
            "id": "4895619",
            "problem": "A $48$-year-old woman with diffuse cutaneous systemic sclerosis presents with an abrupt rise in serum creatinine from $0.9\\ \\text{mg/dL}$ to $3.4\\ \\text{mg/dL}$ over $48$ hours, new-onset oliguria, and mild headache. She has been taking prednisone $40\\ \\text{mg/day}$ for the past $3$ weeks. Blood pressure is $124/76\\ \\text{mm Hg}$ on two measurements $30$ minutes apart. She has no fever, has clear lungs, and there is no edema. She has not received diuretics, nonsteroidal anti-inflammatory drugs, or contrast agents. Funduscopic examination shows mild arteriolar narrowing without hemorrhages or exudates. You are given the following candidate data patterns drawn at the same time point, each comprising urine indices and peripheral blood markers.\n\nUsing the core principles of renal sodium and urea handling in states of renal hypoperfusion and the pathophysiology of thrombotic microangiopathy, which option most specifically supports the diagnosis of normotensive scleroderma renal crisis rather than prerenal azotemia at presentation?\n\nA. Urine sodium $=8\\ \\text{mEq/L}$, urine creatinine $=150\\ \\text{mg/dL}$, urine urea $=600\\ \\text{mg/dL}$; serum sodium $=140\\ \\text{mEq/L}$, serum creatinine $=3.4\\ \\text{mg/dL}$, blood urea nitrogen $=60\\ \\text{mg/dL}$. Peripheral smear: schistocytes $3\\%$; lactate dehydrogenase $=950\\ \\text{U/L}$; haptoglobin $<10\\ \\text{mg/dL}$; platelets $=65\\times 10^{9}/\\text{L}$; ADAMTS13 activity $=65\\%$.\n\nB. Urine sodium $=10\\ \\text{mEq/L}$, urine creatinine $=100\\ \\text{mg/dL}$, urine urea $=700\\ \\text{mg/dL}$; serum sodium $=140\\ \\text{mEq/L}$, serum creatinine $=3.4\\ \\text{mg/dL}$, blood urea nitrogen $=80\\ \\text{mg/dL}$. Peripheral smear: no schistocytes; lactate dehydrogenase $=200\\ \\text{U/L}$; haptoglobin $=120\\ \\text{mg/dL}$; platelets $=250\\times 10^{9}/\\text{L}$.\n\nC. Urine sodium $=60\\ \\text{mEq/L}$, urine creatinine $=40\\ \\text{mg/dL}$, urine urea $=300\\ \\text{mg/dL}$; serum sodium $=140\\ \\text{mEq/L}$, serum creatinine $=3.4\\ \\text{mg/dL}$, blood urea nitrogen $=60\\ \\text{mg/dL}$. Peripheral smear: schistocytes $2\\%$; lactate dehydrogenase $=1200\\ \\text{U/L}$; haptoglobin $<10\\ \\text{mg/dL}$; platelets $=80\\times 10^{9}/\\text{L}$.\n\nD. Urine sodium $=9\\ \\text{mEq/L}$, urine creatinine $=120\\ \\text{mg/dL}$, urine urea $=500\\ \\text{mg/dL}$; serum sodium $=140\\ \\text{mEq/L}$, serum creatinine $=3.4\\ \\text{mg/dL}$, blood urea nitrogen $=60\\ \\text{mg/dL}$. Peripheral smear: schistocytes $3\\%$; lactate dehydrogenase $=1000\\ \\text{U/L}$; haptoglobin $<10\\ \\text{mg/dL}$; platelets $=55\\times 10^{9}/\\text{L}$; ADAMTS13 activity $=4\\%$.\n\nSelect one best answer.",
            "solution": "The user wants me to validate the problem statement and, if valid, provide a detailed solution to a clinical reasoning problem in internal medicine.\n\n## Problem Validation\n\n### Step 1: Extract Givens\n\n-   **Patient Profile**: A $48$-year-old woman with diffuse cutaneous systemic sclerosis.\n-   **Clinical Presentation**:\n    -   Abrupt rise in serum creatinine from $0.9\\ \\text{mg/dL}$ to $3.4\\ \\text{mg/dL}$ over $48$ hours.\n    -   New-onset oliguria.\n    -   Mild headache.\n    -   Blood pressure is $124/76\\ \\text{mm Hg}$.\n-   **Medication History**: Prednisone $40\\ \\text{mg/day}$ for the past $3$ weeks (a known risk factor for scleroderma renal crisis).\n-   **Physical Examination**:\n    -   No fever, clear lungs, no edema.\n    -   Funduscopic examination shows mild arteriolar narrowing without hemorrhages or exudates.\n-   **Exclusions**: No recent exposure to diuretics, nonsteroidal anti-inflammatory drugs, or contrast agents.\n-   **Core Task**: Using principles of renal handling of sodium and urea and the pathophysiology of thrombotic microangiopathy (TMA), identify the data pattern (Option A, B, C, or D) that most specifically supports a diagnosis of normotensive scleroderma renal crisis (SRC) over prerenal azotemia.\n\n### Step 2: Validate Using Extracted Givens\n\n1.  **Scientifically Grounded**: The problem is scientifically sound. Scleroderma renal crisis (SRC) is a well-established, life-threatening complication of systemic sclerosis. The presentation with acute kidney injury (AKI) is classic. Normotensive SRC, while less common than the hypertensive form, accounts for $10-20\\%$ of cases and presents a significant diagnostic challenge. The differential diagnosis with prerenal azotemia is clinically critical. The laboratory parameters provided (urine indices, markers of microangiopathic hemolytic anemia [MAHA]) are the standard tools used in this evaluation. The use of high-dose corticosteroids is a known precipitating factor for SRC. The entire scenario is medically and scientifically realistic.\n2.  **Well-Posed**: The problem is well-posed. It asks for the identification of a specific laboratory pattern that best distinguishes one well-defined clinical entity (normotensive SRC) from another (prerenal azotemia) based on established pathophysiological principles. The provided options contain quantitative data that allow for a definitive and logical analysis. A single best answer can be derived through systematic evaluation.\n3.  **Objective**: The problem is objective. All information is presented as factual clinical data and laboratory values. The question requires an answer based on the application of scientific principles, not on subjective opinion.\n\n### Step 3: Verdict and Action\n\nThe problem statement is valid. It is scientifically grounded, well-posed, and objective. I will proceed with the detailed solution.\n\n## Solution Derivation\n\nThe central task is to distinguish normotensive scleroderma renal crisis (SRC) from prerenal azotemia in a patient with systemic sclerosis presenting with acute kidney injury (AKI). This requires understanding the distinct pathophysiology of each condition.\n\n**Pathophysiology of Prerenal Azotemia**\nPrerenal azotemia results from decreased renal perfusion (e.g., due to volume depletion). The kidney itself is structurally intact. The physiological response is to conserve sodium and water to restore perfusion pressure. This is mediated by the renin-angiotensin-aldosterone system (RAAS) and antidiuretic hormone (ADH).\n-   **Renal Indices**: The healthy tubules avidly reabsorb sodium and urea. This leads to characteristic urine findings:\n    -   Low urine sodium concentration ($U_{Na} < 20 \\text{ mEq/L}$).\n    -   Low fractional excretion of sodium ($FENa < 1\\%$).\n    -   Concentrated urine.\n    -   Disproportionate elevation of blood urea nitrogen (BUN) relative to serum creatinine ($S_{Cr}$), with a BUN/$S_{Cr}$ ratio often greater than $20:1$.\n-   **Hematologic Findings**: Prerenal azotemia is a purely hemodynamic state; it does not involve hemolysis or platelet consumption. The peripheral blood smear, platelet count, lactate dehydrogenase (LDH), and haptoglobin levels are normal.\n\n**Pathophysiology of Scleroderma Renal Crisis (SRC)**\nSRC is an intrinsic renal disease, specifically a form of thrombotic microangiopathy (TMA). The primary event is widespread endothelial injury in the renal arterioles and capillaries. This triggers platelet activation, fibrin deposition, and the formation of microthrombi.\n-   **Renal Consequences**: The microvascular obstruction causes severe renal ischemia and a precipitous drop in the glomerular filtration rate (GFR), leading to AKI. The renal injury is intrinsic. While intense RAAS activation occurs, leading to sodium retention, tubular function can be compromised by ischemia. Therefore, the $FENa$ can be low ($<1\\%$) early in the course (mimicking prerenal azotemia) or high ($>1-2\\%$) as ischemic tubular injury progresses to acute tubular necrosis (ATN).\n-   **Hematologic Consequences (MAHA)**: The fibrin strands in the microvasculature shear passing red blood cells, causing mechanical hemolysis. This results in a characteristic set of laboratory findings:\n    -   **Schistocytes** (fragmented red blood cells) on the peripheral blood smear.\n    -   **Thrombocytopenia** due to platelet consumption in microthrombi.\n    -   **Elevated LDH** released from hemolyzed red blood cells and ischemic tissues.\n    -   **Low haptoglobin**, which is consumed by binding free hemoglobin from hemolysis.\n-   **Distinction from other TMAs**: It is crucial to distinguish SRC from other TMAs, particularly thrombotic thrombocytopenic purpura (TTP). TTP is caused by a severe deficiency in the activity of the ADAMTS13 enzyme. In SRC, ADAMTS13 activity is typically normal or near-normal.\n\nThe most specific feature differentiating SRC from prerenal azotemia is the presence of MAHA. While urine indices can overlap, the hematologic evidence of TMA is pathognomonic for SRC in this clinical context and definitively absent in prerenal azotemia.\n\n### Option-by-Option Analysis\n\nWe will calculate the $FENa$ for each option using the formula: $FENa (\\%) = \\frac{U_{Na} \\times S_{Cr}}{S_{Na} \\times U_{Cr}} \\times 100$.\n\n**A. Urine sodium $=8\\ \\text{mEq/L}$, urine creatinine $=150\\ \\text{mg/dL}$, urine urea $=600\\ \\text{mg/dL}$; serum sodium $=140\\ \\text{mEq/L}$, serum creatinine $=3.4\\ \\text{mg/dL}$, blood urea nitrogen $=60\\ \\text{mg/dL}$. Peripheral smear: schistocytes $3\\%$; lactate dehydrogenase $=950\\ \\text{U/L}$; haptoglobin $<10\\ \\text{mg/dL}$; platelets $=65\\times 10^{9}/\\text{L}$; ADAMTS13 activity $=65\\%$.**\n\n-   **Renal Indices**:\n    -   $FENa = \\frac{8 \\times 3.4}{140 \\times 150} \\times 100 = \\frac{27.2}{21000} \\times 100 \\approx 0.13\\%$.\n    -   The $FENa$ is very low ($<1\\%$), a pattern typically associated with prerenal azotemia.\n    -   The BUN/$S_{Cr}$ ratio is $60/3.4 \\approx 17.6$, which is not strongly suggestive of a prerenal state but does not exclude it.\n-   **Hematologic Findings**:\n    -   The results show a clear picture of MAHA: significant schistocytes ($3\\%$), severe thrombocytopenia ($65\\times 10^{9}/\\text{L}$), markedly elevated LDH ($950\\ \\text{U/L}$), and depleted haptoglobin ($<10\\ \\text{mg/dL}$).\n    -   The ADAMTS13 activity of $65\\%$ is near-normal, effectively ruling out TTP.\n-   **Conclusion**: This option presents a classic diagnostic challenge. The urine indices mimic prerenal azotemia, but the hematologic findings are pathognomonic for a non-TTP TMA. In a patient with scleroderma, this combination is highly specific for SRC. The presence of TMA markers is the key feature that distinguishes SRC from prerenal azotemia.\n\n**Verdict: Correct**\n\n**B. Urine sodium $=10\\ \\text{mEq/L}$, urine creatinine $=100\\ \\text{mg/dL}$, urine urea $=700\\ \\text{mg/dL}$; serum sodium $=140\\ \\text{mEq/L}$, serum creatinine $=3.4\\ \\text{mg/dL}$, blood urea nitrogen $=80\\ \\text{mg/dL}$. Peripheral smear: no schistocytes; lactate dehydrogenase $=200\\ \\text{U/L}$; haptoglobin $=120\\ \\text{mg/dL}$; platelets $=250\\times 10^{9}/\\text{L}$.**\n\n-   **Renal Indices**:\n    -   $FENa = \\frac{10 \\times 3.4}{140 \\times 100} \\times 100 = \\frac{34}{14000} \\times 100 \\approx 0.24\\%$.\n    -   The $FENa$ is low ($<1\\%$).\n    -   The BUN/$S_{Cr}$ ratio is $80/3.4 \\approx 23.5$, which is greater than $20:1$.\n-   **Hematologic Findings**:\n    -   All markers for TMA are negative: no schistocytes, normal LDH, normal haptoglobin, and normal platelet count.\n-   **Conclusion**: This set of data is the textbook definition of prerenal azotemia. There is no evidence of SRC.\n\n**Verdict: Incorrect**\n\n**C. Urine sodium $=60\\ \\text{mEq/L}$, urine creatinine $=40\\ \\text{mg/dL}$, urine urea $=300\\ \\text{mg/dL}$; serum sodium $=140\\ \\text{mEq/L}$, serum creatinine $=3.4\\ \\text{mg/dL}$, blood urea nitrogen $=60\\ \\text{mg/dL}$. Peripheral smear: schistocytes $2\\%$; lactate dehydrogenase $=1200\\ \\text{U/L}$; haptoglobin $<10\\ \\text{mg/dL}$; platelets $=80\\times 10^{9}/\\text{L}$.**\n\n-   **Renal Indices**:\n    -   $FENa = \\frac{60 \\times 3.4}{140 \\times 40} \\times 100 = \\frac{204}{5600} \\times 100 \\approx 3.6\\%$.\n    -   The $FENa$ is high ($>2\\%$), which indicates established intrinsic renal parenchymal injury, such as ATN.\n-   **Hematologic Findings**:\n    -   There is clear evidence of MAHA (schistocytes, thrombocytopenia, high LDH, low haptoglobin), consistent with SRC.\n-   **Conclusion**: This pattern represents an intrinsic AKI with TMA, very likely SRC that has progressed to ATN. However, the question asks which option *most specifically supports SRC rather than prerenal azotemia*. In this case, the high $FENa$ already rules out prerenal azotemia. Option A is superior because it illustrates the more subtle and challenging diagnostic scenario where urine indices are misleadingly \"prerenal,\" forcing reliance on the highly specific TMA markers to make the diagnosis of SRC.\n\n**Verdict: Incorrect**\n\n**D. Urine sodium $=9\\ \\text{mEq/L}$, urine creatinine $=120\\ \\text{mg/dL}$, urine urea $=500\\ \\text{mg/dL}$; serum sodium $=140\\ \\text{mEq/L}$, serum creatinine $=3.4\\ \\text{mg/dL}$, blood urea nitrogen $=60\\ \\text{mg/dL}$. Peripheral smear: schistocytes $3\\%$; lactate dehydrogenase $=1000\\ \\text{U/L}$; haptoglobin $<10\\ \\text{mg/dL}$; platelets $=55\\times 10^{9}/\\text{L}$; ADAMTS13 activity $=4\\%$.**\n\n-   **Renal Indices**:\n    -   $FENa = \\frac{9 \\times 3.4}{140 \\times 120} \\times 100 = \\frac{30.6}{16800} \\times 100 \\approx 0.18\\%$.\n    -   The $FENa$ is low ($<1\\%$).\n-   **Hematologic Findings**:\n    -   There is florid MAHA.\n    -   Crucially, the ADAMTS13 activity is $4\\%$. Activity below $10\\%$ is diagnostic for TTP.\n-   **Conclusion**: This laboratory profile is diagnostic of TTP, not SRC. While TTP and SRC are both TMAs, they are distinct etiologies. The question specifically asks for evidence supporting SRC.\n\n**Verdict: Incorrect**\n\n**Summary**\nOption A provides the most specific support for a diagnosis of normotensive SRC over prerenal azotemia. It presents the exact clinical dilemma where urine indices mimic a prerenal state, but the pathognomonic hematologic findings of a non-TTP TMA correctly identify the underlying pathology of SRC. This forces the clinician to recognize the TMA as the overriding diagnostic feature, which is the core of the question.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Once a diagnosis of SRC is made, immediate and precise management of severe hypertension is paramount to salvaging renal function and preventing further end-organ damage. This exercise simulates the critical first step in therapeutic intervention: setting a safe blood pressure goal. You will use the standard formula to calculate the mean arterial pressure ($MAP$) and then apply established principles for managing a hypertensive emergency to determine a target $MAP$ for the first hour of treatment. This practice reinforces the crucial clinical principle of controlled blood pressure reduction, which aims to mitigate hypertensive damage without inducing iatrogenic hypoperfusion injury to the already vulnerable kidneys and brain .",
            "id": "4895622",
            "problem": "A patient with diffuse cutaneous systemic sclerosis presents with abrupt onset of severe hypertension, headache, rising serum creatinine, and thrombocytopenia, consistent with scleroderma renal crisis (SRC). On arrival, the noninvasive blood pressure is measured as systolic blood pressure (SBP) $200\\ \\mathrm{mmHg}$ and diastolic blood pressure (DBP) $120\\ \\mathrm{mmHg}$. Using the standard clinical approximation for mean arterial pressure (MAP), where $MAP$ is calculated from $SBP$ and $DBP$ as $MAP = (SBP + 2 \\times DBP)/3$, first compute the initial $MAP$. Then, applying the well-established hypertensive emergency principle that early blood pressure reduction should avoid precipitating renal and cerebral hypoperfusion, select a single safe reduction target equal to the midpoint of the commonly recommended first-hour relative reduction range (that is, choose a fractional decrease halfway between $10\\%$ and $20\\%$ of the initial $MAP$). Using that midpoint as the planned fractional $MAP$ reduction for the first hour, compute the target $MAP$ at the end of the first hour.\n\nReport only the target $MAP$ at the end of the first hour, rounded to three significant figures, and express the value in $\\mathrm{mmHg}$.",
            "solution": "### Step 1: Problem Validation\n\n**1. Extract Givens:**\n*   **Initial Blood Pressure:** Systolic Blood Pressure ($SBP$) = $200 \\ \\mathrm{mmHg}$, Diastolic Blood Pressure ($DBP$) = $120 \\ \\mathrm{mmHg}$.\n*   **MAP Formula:** $MAP = \\frac{SBP + 2 \\times DBP}{3}$.\n*   **Reduction Target:** The first-hour reduction should be the midpoint of the range from $10\\%$ to $20\\%$ of the initial $MAP$.\n*   **Final Answer Requirement:** Report the target $MAP$ at the end of the first hour, rounded to three significant figures.\n\n**2. Validate Using Extracted Givens:**\n*   **Scientific Grounding (Critical):** The problem is scientifically grounded. The clinical presentation is a classic description of scleroderma renal crisis (SRC). The initial blood pressure values ($200/120 \\ \\mathrm{mmHg}$) are severe but entirely plausible for a hypertensive emergency. The formula provided for approximating mean arterial pressure, $MAP = (SBP + 2 \\times DBP)/3$, is a standard and widely used clinical heuristic. The principle of controlled blood pressure reduction (avoiding precipitous drops) and the specific target range of $10\\%-20\\%$ in the first hour are consistent with established guidelines for managing hypertensive emergencies.\n*   **Well-Posed:** The problem is well-posed. It provides all necessary initial values, a precise formula for calculation, and a clear, unambiguous rule for determining the reduction target. A unique, stable, and meaningful solution can be derived from the given information.\n*   **Objective (Critical):** The problem is stated in objective, quantitative terms, free from subjective language or opinion.\n\n**3. Verdict and Action:**\nThe problem is **valid**. It is scientifically sound, well-posed, and objective. I will proceed with the solution.\n\n### Step 2: Solution\n\nThe problem requires a two-step calculation: first, to determine the initial mean arterial pressure ($MAP_{initial}$), and second, to calculate the target mean arterial pressure ($MAP_{target}$) after a specified fractional reduction.\n\n**1. Calculate the Initial Mean Arterial Pressure ($MAP_{initial}$)**\n\nThe initial systolic blood pressure ($SBP$) is given as $200 \\ \\mathrm{mmHg}$, and the initial diastolic blood pressure ($DBP$) is $120 \\ \\mathrm{mmHg}$. The formula for calculating the mean arterial pressure is provided as:\n$$MAP = \\frac{SBP + 2 \\times DBP}{3}$$\nSubstituting the given values into this formula:\n$$MAP_{initial} = \\frac{200 + 2 \\times 120}{3}$$\n$$MAP_{initial} = \\frac{200 + 240}{3}$$\n$$MAP_{initial} = \\frac{440}{3} \\ \\mathrm{mmHg}$$\nFor intermediate calculations, it is best to retain this exact fractional form to avoid rounding errors.\n\n**2. Determine the Target Mean Arterial Pressure ($MAP_{target}$)**\n\nThe problem specifies that the target reduction should be the midpoint of the recommended first-hour relative reduction range of $10\\%$ to $20\\%$. Let the fractional reduction be denoted by $f$. The range for $f$ is $[0.10, 0.20]$.\n\nThe midpoint of this range is:\n$$f_{target} = \\frac{0.10 + 0.20}{2} = \\frac{0.30}{2} = 0.15$$\nThis corresponds to a $15\\%$ reduction in the initial $MAP$.\n\nThe target $MAP$ after this reduction is calculated as:\n$$MAP_{target} = MAP_{initial} \\times (1 - f_{target})$$\nSubstituting the values for $MAP_{initial}$ and $f_{target}$:\n$$MAP_{target} = \\left(\\frac{440}{3}\\right) \\times (1 - 0.15)$$\n$$MAP_{target} = \\left(\\frac{440}{3}\\right) \\times 0.85$$\nTo compute the product, we can express $0.85$ as a fraction, $\\frac{85}{100}$ or $\\frac{17}{20}$:\n$$MAP_{target} = \\frac{440}{3} \\times \\frac{17}{20}$$\n$$MAP_{target} = \\frac{440 \\times 17}{3 \\times 20}$$\n$$MAP_{target} = \\frac{22 \\times 20 \\times 17}{3 \\times 20}$$\n$$MAP_{target} = \\frac{22 \\times 17}{3}$$\n$$MAP_{target} = \\frac{374}{3}$$\nNow, we compute the decimal value to perform the rounding:\n$$MAP_{target} = 124.666... \\ \\mathrm{mmHg}$$\n\n**3. Round to Three Significant Figures**\n\nThe problem requires the final answer to be rounded to three significant figures. The calculated value is $124.666...$.\nThe first three significant figures are $1$, $2$, and $4$. The fourth digit is $6$. Since $6 \\ge 5$, we round up the third digit.\nThus, the rounded target $MAP$ is $125 \\ \\mathrm{mmHg}$.",
            "answer": "$$\\boxed{125}$$"
        }
    ]
}